Leap Therapeutics, Inc. (5MC.F)
| Previous close | 2.6800 |
| Open | 2.6200 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 2.6200 - 2.6200 |
| 52-week range | 1.0300 - 8.5000 |
| Volume | |
| Avg. volume | 64 |
| Market cap | 100.253M |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise
- PR Newswire
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023.
- PR Newswire
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced new data from Part A of the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC), to be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers S
